Innate & Adaptive ImmunityApril 20, 20267 min read

Everything You Need to Know About Antigen presentation for Step 1

Deep dive: definition, pathophysiology, clinical presentation, diagnosis, treatment, HY associations for Antigen presentation. Include First Aid cross-references.

Antigen presentation is one of those “small concept, huge payoff” topics: it explains why some infections trigger strong T-cell responses, why certain immunodeficiencies are catastrophic, why transplant rejection happens, and why tumors try to hide. If you can cleanly answer who presents what to whom, where, and with which MHC, you’ll crush a big chunk of Step 1 immunology.

Big Picture: What Is Antigen Presentation?

Antigen presentation is the process by which cells display peptide fragments on their surface bound to major histocompatibility complex (MHC) molecules so that T cells can “see” them.

  • T cells do not recognize free-floating antigen.
  • T cells recognize peptide + MHC via the T-cell receptor (TCR).

A classic Step framework:

  • MHC I presents endogenous (intracellular) peptides → CD8+ cytotoxic T cells
  • MHC II presents exogenous (extracellular) peptides → CD4+ helper T cells
💡

First Aid cross-reference: Immunology → Antigen presentation; MHC I vs MHC II; T-cell activation; Cytokines.

The “Who/What/Where” Table (High Yield)

PathwayAntigen sourcePresented onExpressed onRecognized byCoreceptorMain job
EndogenousViral proteins, tumor proteins, cytosolic proteinsMHC IAll nucleated cells (NOT RBCs)CD8+ T cellsCD8 binds MHC IKill infected or malignant cells
ExogenousBacteria, toxins, extracellular proteinsMHC IIAPCs only (dendritic cells, macrophages, B cells)CD4+ T cellsCD4 binds MHC IIHelp B cells, activate macrophages, coordinate immunity

Memory hook:

  • 1 × 8 = 8 → MHC I → CD8
  • 2 × 4 = 8 → MHC II → CD4

The Molecular Machinery (Know These Players)

MHC I Pathway (Endogenous → CD8)

Goal: Show what’s happening inside the cell.

Key steps:

  1. Protein in cytosol gets degraded by the proteasome into peptides.
  2. Peptides are transported into the rough ER by TAP (Transporter associated with Antigen Processing).
  3. Peptide loads onto MHC I in the ER.
  4. MHC I–peptide complex travels through Golgi → surface.

High-yield associations

  • TAP deficiency → poor MHC I antigen presentation → weak CD8 response.
  • Viruses may downregulate MHC I to evade CD8 killing (but this can trigger NK cells).
💡

First Aid cross-reference: Immunodeficiencies (Bare lymphocyte syndromes); NK cells; Viral immune evasion.

MHC II Pathway (Exogenous → CD4)

Goal: Show what the cell has eaten.

Key steps:

  1. APC endocytoses/phagocytoses extracellular antigen.
  2. Antigen is degraded in acidified endosomes/lysosomes.
  3. MHC II is made in the ER, but its peptide-binding groove is temporarily blocked by the invariant chain.
  4. Invariant chain is cleaved → leaves CLIP sitting in the groove.
  5. HLA-DM swaps CLIP for the real antigenic peptide.
  6. MHC II–peptide complex goes to the surface.

High-yield associations

  • HLA-DM is essential for proper MHC II loading.
  • APCs are professional antigen-presenting cells: dendritic cells, macrophages, B cells.
💡

First Aid cross-reference: APCs; MHC II processing; T helper subsets.

Cross-Presentation & Cross-Dressing (The “Trick Question” Zone)

Cross-presentation (Step-relevant)

Some cells—especially dendritic cells—can take exogenous antigens and present them on MHC I to activate CD8+ T cells.

Why it matters:

  • Helpful for initiating CD8 responses against viruses or tumors that don’t directly infect dendritic cells.

Buzzphrase you may see: “Dendritic cell primes naïve CD8 T cells via cross-presentation.”

T-Cell Activation: The Signals You Must Know

Antigen presentation is necessary but not sufficient.

Signal 1: Specificity

  • TCR binds peptide-MHC
  • CD4/CD8 coreceptor binds MHC II/I respectively

Signal 2: Costimulation (the exam favorite)

  • APC B7 (CD80/86) binds T cell CD28
  • Without this second signal → anergy (functional inactivation)

Clinical correlation (very HY):

  • CTLA-4 on T cells inhibits by binding B7 (higher affinity than CD28).
  • Drugs:
    • Abatacept (CTLA-4-Ig) blocks costimulation → used in RA and transplant contexts.
    • Ipilimumab (anti–CTLA-4) boosts T-cell activity → cancer immunotherapy, but can cause autoimmune-like toxicities.
💡

First Aid cross-reference: T-cell activation; Immunosuppressants; Monoclonal antibodies.

Signal 3: Cytokines (direct differentiation)

  • Determines Th1 vs Th2 vs Th17 vs Treg polarization (Step loves the cytokines).

Pathophysiology: What Happens When Antigen Presentation Fails?

1) MHC I deficiency → CD8 problems (Bare Lymphocyte Syndrome Type I)

  • Often due to TAP defect
  • ↓ MHC I on surface → ↓ CD8 T cells / impaired cytotoxic response

Clinical pattern:

  • Recurrent viral infections (can also have some bacterial infections)
  • Typically less severe than MHC II deficiency

2) MHC II deficiency → CD4 problems (Bare Lymphocyte Syndrome Type II)

  • Due to defective transcription factors needed for MHC II expression (not usually HLA-DM on exams for this syndrome)
  • ↓ CD4 T cells → secondary ↓ B-cell activation and class switching

Clinical pattern (severe):

  • Recurrent bacterial, viral, fungal, and parasitic infections
  • Failure to thrive, chronic diarrhea, opportunistic infections
💡

First Aid cross-reference: Bare lymphocyte syndromes; Hyper-IgM; SCID (compare/contrast).

Clinical Presentation: How It Shows Up in Vignettes

When you should think “antigen presentation problem”

  • Recurrent infections with unusual severity
  • Infections starting early in life
  • Opportunistic organisms (suggesting T-cell dysfunction)
  • Poor response to vaccines (especially those needing T-cell help)

Clues for MHC II problems (CD4 deficiency pattern):

  • Low CD4 counts
  • Low class-switched antibodies (IgG, IgA, IgE)
  • Severe opportunistic infections (similar “feel” to advanced HIV, but congenital)

Clues for MHC I problems (CD8 deficiency pattern):

  • Viral susceptibility
  • Reduced CD8 cells

Diagnosis: What You’d Measure (and What You’d See)

Core tests in question stems

  • Flow cytometry:
    • MHC I or MHC II expression on cells
    • CD4 and CD8 counts
  • Immunoglobulin levels:
    • Often globally impaired in MHC II deficiency due to loss of T-cell help
  • Functional assays (less common in Step stems):
    • T-cell proliferation with mitogens/antigens

Pattern summary

DisorderExpected finding
MHC I/TAP defect↓ MHC I expression, ↓ CD8 function/cell numbers
MHC II transcription defect↓ MHC II expression, ↓ CD4 T cells, weak antibody class switching

Treatment: What Step Wants You to Say

For congenital, severe antigen presentation defects:

  • Infection prophylaxis and aggressive treatment
  • Hematopoietic stem cell transplant (HSCT) can be definitive in severe combined immune dysfunction phenotypes (often emphasized for severe T-cell defects)

For immune modulation in clinical medicine (antigen presentation/costimulation adjacent):

  • Abatacept (CTLA-4-Ig): blocks B7–CD28 → reduces T-cell activation
  • Checkpoint inhibitors (e.g., anti–CTLA-4, anti–PD-1): enhance T-cell responses against tumors, with immune-related adverse events

High-Yield Associations & Classic Exam Traps

NK cells: “Missing self” surveillance

  • NK cells are inhibited by normal MHC I.
  • If a virus downregulates MHC I → NK cells may kill the cell due to loss of inhibition.

NK killing tools to remember:

  • Perforin creates pores
  • Granzymes induce apoptosis
💡

First Aid cross-reference: NK cells; Type I interferons; Perforin/granzyme.

Transplant rejection (why MHC matters)

  • Allorecognition: recipient T cells recognize donor MHC as foreign.
  • MHC differences are a key driver of rejection → basis for HLA matching.
💡

First Aid cross-reference: Transplant rejection; HLA associations.

Superantigens: bypass normal antigen processing

Organisms like Staph aureus (TSST-1) can activate tons of T cells by bridging:

  • MHC II on APCs to the TCR (outside the peptide-binding groove)

Result:

  • Massive cytokine release → toxic shock picture
💡

First Aid cross-reference: Superantigens; Toxic shock syndrome; Cytokines.

“APCs only” list (don’t miss this)

Professional APCs that express MHC II:

  • Dendritic cells (best at priming naïve T cells)
  • Macrophages
  • B cells

Common distractor: Epithelial cells are not “professional APCs” (though some can express MHC II in inflammation—usually beyond Step expectations).

Rapid Review: Step 1 Must-Know Points

  • MHC I: endogenous → proteasome → TAP → ER → surface → CD8
  • MHC II: exogenous → endosome/lysosome → invariant chain/CLIP → HLA-DM → surface → CD4
  • Costimulation: B7 (APC) to CD28 (T cell); absence → anergy
  • CTLA-4 inhibits; abatacept blocks costimulation; checkpoint inhibitors remove brakes
  • Bare lymphocyte syndromes:
    • Type I (TAP/MHC I) → CD8 issues (viral susceptibility)
    • Type II (MHC II expression) → CD4 issues (severe, broad infections)
  • NK cells kill cells with low MHC I (“missing self”)
Back to all articles